| Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria |
639 |
| Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
284 |
| Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
265 |
| Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
237 |
| Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
226 |
| Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
167 |
| Global, regional, and national burden of multiple sclerosis 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
127 |
| The glymphatic pathway in neurological disorders |
125 |
| Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies |
122 |
| Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
115 |
| Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management |
107 |
| Stroke in China: advances and challenges in epidemiology, prevention, and management |
95 |
| Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management |
92 |
| Small vessel disease: mechanisms and clinical implications |
77 |
| Global, regional, and national burden of epilepsy, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
67 |
| Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications |
65 |
| Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model |
62 |
| The pathophysiology of migraine: implications for clinical management |
59 |
| An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models |
57 |
| Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis |
57 |
| Serum GFAP and UCH-L1 for prediction of absence of intracranial injuries on head CT (ALERT-TBI): a multicentre observational study |
57 |
| Case-mix, care pathways, and outcomes in patients with traumatic brain injury in CENTER-TBI: a European prospective, multicentre, longitudinal, cohort study |
55 |
| Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
55 |
| Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data |
54 |
| Association between circadian rhythms and neurodegenerative diseases |
53 |
| Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry |
51 |
| Investigation of frailty as a moderator of the relationship between neuropathology and dementia in Alzheimer's disease: a cross-sectional analysis of data from the Rush Memory and Aging Project |
49 |
| CSF and blood biomarkers for Parkinson's disease |
49 |
| Classification and management of adult inflammatory myopathies |
49 |
| Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson's disease: a double-blind, randomised controlled trial |
48 |
| Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders |
44 |
| Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study |
44 |
| Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study |
43 |
| Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications |
43 |
| Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data |
43 |
| Nutrition and prevention of cognitive impairment |
42 |
| Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data |
41 |
| Selective autophagy as a potential therapeutic target for neurodegenerative disorders |
41 |
| Global brain inflammation in stroke |
38 |
| Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan |
37 |
| Effect of general anaesthesia on functional outcome in patients with anterior circulation ischaemic stroke having endovascular thrombectomy versus standard care: a meta-analysis of individual patient data |
37 |
| Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase randomised, double-blind, placebo-controlled trial with an open-label extension |
36 |
| Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial |
36 |
| Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned |
36 |
| Epidemiology, aetiology, and management of ischaemic stroke in young adults |
35 |
| Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial |
35 |
| Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial |
35 |
| Diagnosis, pathophysiology, and management of cluster headache |
34 |
| Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study |
34 |
| Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study |
34 |
| Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies |
33 |
| Circadian and circaseptan rhythms in human epilepsy: a retrospective cohort study |
33 |
| Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
33 |
| Gait impairments in Parkinson's disease |
33 |
| Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial |
32 |
| The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications |
32 |
| Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial |
32 |
| Risk factors for non-motor symptoms in Parkinson's disease |
31 |
| Traumatic brain injury in China |
31 |
| Comorbidities, treatment, and pathophysiology in restless legs syndrome |
31 |
| In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study |
31 |
| Diagnostic challenges in epilepsy: seizure under-reporting and seizure detection |
30 |
| Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial |
29 |
| Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study |
29 |
| Focused ultrasound subthalamotomy in patients with asymmetric Parkinson's disease: a pilot study |
28 |
| Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study |
28 |
| Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial |
28 |
| Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study |
28 |
| Global, regional, and national burden of motor neuron diseases 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 |
28 |
| Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders |
28 |
| The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders |
28 |
| Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial |
27 |
| The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study |
26 |
| Association between plasma GFAP concentrations and MRI abnormalities in patients with CT-negative traumatic brain injury in the TRACK-TBI cohort: a prospective multicentre study |
26 |
| Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation |
25 |
| The effect of &ITAPOE&IT and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study |
25 |
| Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy |
25 |
| Network imaging biomarkers: insights and clinical applications in Parkinson's disease |
25 |
| Cortical neuronal densities and cerebral white matter demyelination in multiple sclerosis: a retrospective study |
25 |
| Therapeutic interventions in patients with prolonged disorders of consciousness |
24 |
| Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders |
24 |
| Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial |
24 |
| Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data |
24 |
| Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial |
23 |
| Association between pathological and MRI findings in multiple sclerosis |
23 |
| Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study |
23 |
| Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis |
23 |
| Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase randomised, placebo-controlled, double-blind study |
23 |
| Cognitive and neuroimaging features and brain beta-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study |
23 |
| Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial |
23 |
| LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study |
23 |
| Effectiveness and costs of specialised physiotherapy given via ParkinsonNet: a retrospective analysis of medical claims data |
22 |
| An exoskeleton controlled by an epidural wireless brain-machine interface in a tetraplegic patient: a proof-of-concept demonstration |
22 |
| Pathophysiology, prevention, and treatment of medication overuse headache |
22 |
| Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial |
21 |
| Parkinson's disease in the Western Pacific Region |
21 |
| Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study |
21 |
| Cerebral microbleeds and stroke risk after ischaemic stroke or transient ischaemic attack: a pooled analysis of individual patient data from cohort studies |
21 |
| Implications of sleep disturbance and inflammation for Alzheimer's disease dementia |
21 |
| Stroke-heart syndrome: clinical presentation and underlying mechanisms |
21 |
| Circadian rhythm and epilepsy |
21 |
| Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study |
20 |
| Prediction of late seizures after ischaemic stroke with a novel prognostic model (the SeLECT score): a multivariable prediction model development and validation study |
20 |
| Use of brain diffusion tensor imaging for the prediction of long-term neurological outcomes in patients after cardiac arrest: a multicentre, international, prospective, observational, cohort study |
20 |
| Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon 4 haplotype status: a community-based cohort study |
19 |
| Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis |
19 |
| Stroke genetics: discovery, biology, and clinical applications |
19 |
| Clinical application of next-generation sequencing to the practice of neurology |
18 |
| Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase randomised, placebo-controlled, multicentre, dose-ranging study |
18 |
| Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial |
18 |
| Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration: a randomised, double-blind, controlled trial and an open-label extension study |
17 |
| Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial |
17 |
| Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial |
17 |
| Advances in the diagnosis and treatment of fungal infections of the CNS |
17 |
| Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis |
17 |
| Pharyngeal electrical stimulation for early decannulation in tracheotomised patients with neurogenic dysphagia after stroke (PHAST-TRAC): a prospective, single-blinded, randomised trial |
17 |
| Safety and efficacy of eculizumab in Guillain-Barre syndrome: a multicentre, double-blind, randomised phase 2 trial |
16 |
| Clinical presentation, diagnosis, and management of fetal alcohol spectrum disorder |
16 |
| Migraine and the trigeminovascular system-40 years and counting |
16 |
| Restenosis and risk of stroke after stenting or endarterectomy for symptomatic carotid stenosis in the International Carotid Stenting Study (ICSS): secondary analysis of a randomised trial |
16 |
| Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches |
16 |
| Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial |
16 |
| Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study |
15 |
| Priorities to reduce the burden of stroke in Latin American countries |
15 |
| Management of epilepsy in women |
15 |
| Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis |
15 |
| Diagnosis and assessment of neuropathic pain through questionnaires |
15 |
| Clinical presentation, management, and pathophysiology of neuropathic itch |
14 |
| Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study |
13 |
| Long-term outcomes of stenting and endarterectomy for symptomatic carotid stenosis: a preplanned pooled analysis of individual patient data |
13 |
| Diagnosis, prognosis, and treatment of leukodystrophies |
13 |
| Neuromodulation in the restoration of function after spinal cord injury |
13 |
| Serotonergic pathology and disease burden in the premotor and motor phase of A53T alpha-synuclein parkinsonism: a cross-sectional study |
12 |
| Sex differences in the evaluation and treatment of acute ischaemic stroke |
12 |
| Safety and efficacy of sphenopalatine ganglion stimulation for chronic cluster headache: a double-blind, randomised controlled trial |
12 |
| MRI in traumatic spinal cord injury: from clinical assessment to neuroimaging biomarkers |
12 |
| Rare coding variants in genes encoding GABA(A) receptors in genetic generalised epilepsies: an exome-based case-control study |
11 |
| Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial |
11 |
| Safety and efficacy of epigallocatechin gallate in multiple system atrophy (PROMESA): a randomised, double-blind, placebo-controlled trial |
11 |
| The hippocampus in multiple sclerosis |
11 |
| Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial |
10 |
| Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial |
9 |
| Survival in patients with spinocerebellar ataxia types and 6 (EUROSCA): a longitudinal cohort study |
9 |
| The roles of surgery and technology in understanding focal epilepsy and its comorbidities |
9 |
| The role of plasminogen activators in stroke treatment: fibrinolysis and beyond |
9 |
| Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study |
8 |
| IgG4-related disease of the central and peripheral nervous systems |
8 |
| Safety and efficacy of sonothrombolysis for acute ischaemic stroke: a multicentre, double-blind, phase randomised controlled trial |
8 |
| Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial |
8 |
| Recent developments in drug-induced movement disorders: a mixed picture |
8 |
| Assessment of a home-based standing frame programme in people with progressive multiple sclerosis (SUMS): a pragmatic, multi-centre, randomised, controlled trial and cost-effectiveness analysis |
7 |
| The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study |
7 |
| Technological advances and changing indications for lumbar puncture in neurological disorders |
6 |
| Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis |
6 |
| Safety and efficacy of co-careldopa as an add-on therapy to occupational and physical therapy in patients after stroke (DARS): a randomised, double-blind, placebo-controlled trial |
6 |
| Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial |
6 |
| Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase randomised, non-inferiority trial (PRASTRO-I) |
5 |
| The neurocritical care of tuberculous meningitis |
5 |
| Stenting for symptomatic vertebral artery stenosis: a preplanned pooled individual patient data analysis |
3 |
